Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Mucositis 3Hematologic Neoplasms 3Graft vs Host Disease 1

Interventions

Methotrexate 5Cyclosporine 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Cyclophosphamide 2fludarabine phosphate 1angiotensin I (1-7) 1Sirolimus 1Nivolumab 1Methylprednisolone 1Idarubicin 1Cytarabine 1Busulfan 1Azacitidine 1Atorvastatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Graft vs Host Disease × angiotensin I (1-7) × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡